Novo cancels development of hemophilia drug
Novo Nordisk has decided to cancel the development of a drug against hemophilia after patients formed anti-drug antibodies in studies with the medicine.
af LEONORA BECK
Novo Nordisk announces that it is shelving the development of the drug vatreptacog alfa for hemophilia patients with inhibitors. The drug was being tested in phase III studies.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
